The non-dilutive nature of the debt financing means Novocure can access substantial capital without issuing new shares, thus avoiding dilution of existing shareholders' equity. This influx of capital is likely to be viewed positively by investors as it enhances the company's liquidity and financial flexibility, enabling it to fund ongoing operations and potentially new projects or research without compromising current stock value. The strategic financial decision underscores management's commitment to both growth and shareholder value, likely leading to a positive short-term impact on NVCR's stock price.